Nivolumab is safe and effective for older kidney cancer patients

Findings from an expanded access programme giving 389 metastatic renal cell carcinoma (RCC) patients access to nivolumab have been published in the journal, Renal Cell Carcinoma. Of the patients on the programme, 32% were at least 70 years of age and 18% were at least 75 years of age. The phase III CheckMate 025 trial […]

read more

The implications of germline mutations in kidney cancer

A recent article in JAMA Oncology, published this month, discusses the use of gene sequencing to identify drug targets in tumours. Gene sequencing has led to incidental findings of germline mutations in patients; changes in the genes of the germ cells that form eggs and sperm and are eventually passed on to the next generation. […]

read more

Be Clear on Cancer Blood in Pee campaign launched

Public Health England (PHE) has launched a national ‘Be Clear on Cancer’ campaign which highlights blood in pee as a key symptom of bladder and kidney cancers. The campaign will encourage everyone to ‘look before they flush’ and visit their GP without delay if they notice blood in their pee, even if it’s just once. Read more […]

read more

Trends in the clinical characteristics of kidney cancer

Researchers from the IRCCS San Raffaele Scientific Institute in Milan, Italy, examined trends in the clinical characteristics of high-risk renal cell carcinoma (RCC) over a 25-year period. Their findings, which were published in Anticancer Research this month, reported that patients are being diagnosed at an older age and with smaller tumours. Also, the number of patients […]

read more

BMI may be related to survival outcomes for non-metastatic kidney cancer

A new study published in Journal of Surgical Oncology last month suggests that high body mass index (BMI) may be related to improved recurrence-free and cancer-specific survival among older patients with non-metastatic clear cell renal cell carcinoma (RCC). It is known that obesity is a risk factor for the development of RCC, but evidence for how obesity […]

read more

Robotic partial nephrectomy found to be mostly superior to other surgeries

A recent review and meta-analysis by researchers from the University of Southern California Keck School of Medicine in Los Angeles, USA, has shown that robotic partial nephrectomy results in mostly better outcomes than either open or laparoscopic partial nephrectomy. The study was published in the Journal of Urology this month. Robotic partial nephrectomy was associated […]

read more

Stereotactic radiotherapy for metastatic kidney cancer

A paper published in the European Journal of Cancer earlier this month reports on the experience of six French hospitals with stereotactic radiotherapy (SRT) for metastatic renal cell carcinoma (RCC) between 2008 and 2015 . This retrospective study showed a 12-month local control rate of metastases of 82.9%. Twenty-five percent of patients with oligometastatic disease […]

read more

First patient to undergo proton beam therapy in the UK

The first patient in the UK to undergo proton beam therapy was treated for prostate cancer at the Rutherford Cancer Centre in Newport, South Wales, in April. This treatment “opens up a new frontier for treatment in the UK”, said his consultant. The Rutherford Cancer Centre is the only clinic in the UK where high-energy […]

read more

First-line tivozanib approved for use in NHS Scotland

We are delighted that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has published advice recommending tivozanib (Fotivda) as a new first-line treatment option for people with advanced renal cell carcinoma (RCC) for use within NHS Scotland. Tivozanib, a tyrosine kinase inhibitor, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is […]

read more

Prevalence of hereditary mutations in kidney cancer patients more than first thought

A recent study published in JAMA Oncology last week examined the prevalence of hereditary mutations in renal cell carcinoma (RCC) associated genes to identify the clinical and pathological factors associated with these mutations. Identification of patients with hereditary RCC is important for cancer screening and, in patients with advanced disease, for treatment and management of […]

read more
Showing 1 to 10 of 338 results
  TOP